Filter By Category
Archives
Share on -
CIDUVECTAMIG
Generic Name: CIDUVECTAMIG
ABSTRACT -
Ciduvectamig is an investigational bispecific antibody designed to simultaneously engage two targets involved in anti-tumour immunity, redirecting cytotoxic T cells toward cancer cells or modulating checkpoint pathways. Bispecific antibodies of this class are being evaluated for solid tumours and haematologic malignancies. Phase I trials are assessing safety, pharmacokinetics, and preliminary efficacy.
DOSAGE -
Intravenous infusion; dosing schedule (flat dose or weight-based, Q1W/Q2W/Q3W) defined in ongoing dose-escalation studies.
SIDE EFFECTS-
- Cytokine release syndrome
- Fatigue
- Infusion-related reactions
- Neutropenia
- Elevated liver enzymes
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion hypersensitivity
- Urticaria
- Angioedema
- Anaphylaxis
DRUG INTERACTIONS-
- Avoid concurrent immunosuppressive therapy
- Live vaccines contraindicated
- Additive immune toxicity with other checkpoint inhibitors
PREAUTONS–
- Step-up dosing may be required to mitigate CRS
- Hepatic function monitoring recommended
- Effective contraception required
- Pre-existing autoimmune conditions may be exacerbated
WARNINGS –
- Severe CRS has been reported with T-cell redirecting bispecifics
- Immune-mediated hepatitis, pneumonitis, and colitis possible
- Patients must be monitored for ≥2 hours post-infusion initially
Share on -
. Developed by